|
Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma. |
|
|
Consulting or Advisory Role - Celgene; Nektar |
Research Funding - Celgene (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Piramal Life Science |
|
|
No Relationships to Disclose |
|
|
Employment - Piramal Life Science |
|
|
No Relationships to Disclose |
|
|
Employment - Piramal Life Science |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Genentech/Roche; GlaxoSmithKline; Novartis; Sanofi |
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Sanofi (Inst) |
|
|
Employment - Piramal Life Science |
|
|
Honoraria - Genentech/Roche; GlaxoSmithKline; Novartis |
Consulting or Advisory Role - Genentech/Roche; GlaxoSmithKline; Novartis |
Research Funding - AstraZeneca (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst) |
|
|
Stock and Other Ownership Interests - Oncosec |
Consulting or Advisory Role - GlaxoSmithKline; Merck; Oncosec |
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck/Schering Plough (Inst); oncosec (Inst); Pfizer (Inst) |